In this month's health quiz, we revisit some of our most popular articles published in recent weeks. This includes news reports on the safety and efficacy of baricitinib, upadacitinib effectiveness as monotherapy, inherited rheumatoid arthritis and our most popular story from this month: The sexual health of patients with musculoskeletal conditions.
In an article published in a recent edition of Arthritis Research & Therapy, Jurgen Wollenhaupt and colleagues from multiple international centers have discovered that tofacitinib 5mg and 10mg twice a day remained effective and safe even after 8 and 9.5 years respectively.
Anne-Mari Mustonen and colleagues in Finland have determined the respective fatty acid (FA) signatures found in the infrapatellar fat pad (IFP) and synovial fluid (SF) of patients with osteoarthritis (OA), and rheumatoid arthritis (RA). While the authors’ findings are inconclusive, they give insight into the complex alterations in fatty acid profiles found in knee arthropathies. They present their findings in a recent Arthritis Research & Therapy.
MRI-guided treat-to-target treatment for patients with rheumatoid arthritis is no better than conventional treat-to-target strategies, researchers reported in JAMA in February. However, in a new commentary posted this month in JAMA, researchers raise some interesting points experts may want to reconsider.
Rheumatoid arthritis patients who failed first-line methotrexate achieved better outcomes with upadacitinib monotherapy, shows a new clinical trials report.
Rheumatoid arthritis patients treated with baricitinib at any point during their treatment, experience improved outcomes, a new clinical trials report shows.
Children born to women who have rheumatoid arthritis during pregnancy could experience life-long health effects due to changes to DNA that alter genetic activity, new research indicates.
A new study reframes rheumatoid arthritis, broadly considered to be a connective tissue disorder, as having deeper neurological ties.
In the phase 3b/4 ORAL Shift study, tofacitinib monotherapy was shown to be comparable to tofacitinib with methotrexate.
A pilot study presented this weekend at EULAR suggests that electro stimulation of the vagus nerve reduces rheumatoid arthritis symptoms.
A new study of AbbVie’s original JAK1-selective inhibitor indicates that it outdoes adalimumab without sacrificing safety in rheumatoid arthritis treatment.
Patients with rheumatoid arthritis receiving combination treatment were more likely to reach ACR20, ACR50, and ACR70 than those receiving methotrexate monotherapy.
Assorted trials and a long-term exposure study of 3770 patients with rheumatoid arthritis further demonstrate baricitinib’s previously recorded safety profile.
Switching from a biologic to a biosimilar did not affect safety or efficacy in a clinical trial of a rheumatoid arthritis biosimilar for etanercept (Enbrel, Amgen), shows a new study.
A second study published in May on the safety and efficacy of biosimilars, shows that switching rheumatoid arthritis patients from etanercept (Enbrel, Amgen) to its biosimilar etanercept-szzs (Erelzi, Sandoz), does not affect efficacy, safety or immunogenicity of etanercept.
Getting more exercise can reduce a woman’s risk of developing rheumatoid arthritis, according to new research.
Serious infections are low, but herpes zoster surpasses expectations, review article shows.
The JAK inhibitor tofacitinib presents a comparably low risk of venous thromboembolism to rheumatoid arthritis patients as do TNFi inhibitors, according to a new study.
Tofacitinib 5 mg or 10 mg twice daily with methotrexate can sustain improvements for 24 months, one study shows.
Baricitinib treatment does not increase the risk for cardiovascular problems in patients with rheumatoid arthritis, according to new research.
Rheumatoid arthritis patients taking tofacitinib could face some increased risks for significant cardiovascular events, depending upon their underlying characteristics, according to the results of a new study.
Rheumatoid arthritis patients and rheumatology providers share many of the same concerns over obstacles that make it harder to reach treat-to-target goals, according to a new study.
The study also found that the overall rate of cardiovascular events was low in the study population, indicating that statins aren’t required for all RA patients.
An editorial in today's issue of Rheumatology makes a strong case for trying subcutaneous methotrexate first before a biologic.
Electronic health records data can be used to create forecast models of disease outcomes in rheumatoid arthritis patients, according to new research.
